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During the drug development process, thousands of poten-
tial candidates are screened, to identify various indicators of 
likely pharmacological side effects. Based on in vivo toxic-
ity testing and subsequent preclinical experiments, many 
of these candidates may not survive and thus progress to 
the drug development phase. The severity of expected side 
effects is also a determinant of progression. A study investi-
gating recent drug withdrawals revealed that majority were 
withdrawn from the market due to their detrimental cardio-
toxic effects.1 One of the prominent clinical cardiotoxic effects 
observed was the ventricular arrhythmia, a characteristic of 
Torsades de Pointes. This arrhythmia can degenerate to ven-
tricular fibrillation resulting in death if there is no immediate 
medical intervention.2 Torsades de Pointes is characterized 
by the pronounced prolongation of the QT interval, which on 
a body surface electrocardiogram (ECG), is measured from 
the beginning of the QRS complex to the end of the T wave. 
This qualitative relationship between QT prolongation and 
risk of Torsades de Pointes is treated as a surrogate of pro-
arrhythmic risk of drugs, and therefore the ICH E14 recom-
mends “testing the effects of new agents on the QT interval 
as well as the collection of cardiovascular adverse events”.2
Physiologically, QT interval is defined as the duration of 
ventricular depolarization and repolarization and is inversely 
related to heart rate, i.e., the faster the heart rate the shorter 
the QT interval.3 Taking this into consideration, any measure-
ment of the QT interval requires correction with respect to the 
heart rate at the time of the ECG reading by applying math-
ematical formulas such as Bazett’s or Fridericia’s. The out-
come is represented as the QTc interval.3 QTc prolongation 
can effect from the inhibition of human ether-a-go-go related 
gene (hERG) channel, which is responsible for the rapid 
component (IKr) of the delayed-rectifier potassium current, 
involved in the cardiomyocytes membrane repolarization.4 
However, disruption of some other ionic currents may also 
contribute to QTc prolongation (e.g., the depolarizing current 
INa and the repolarizing currents ICaL and IKs).
5,6
A closer look at the drug withdrawals related to cardiotoxic 
effects1 demonstrates the fact these incidences were not 
purely the effect of the drug on its own but a combination 
of the effects from the drug and some other underlying con-
dition such as concomitant administration with other drugs. 
Investigation of the various permutations of these conditions 
in a clinical setting is an impossible task. However, recently 
developed, sophisticated mathematical models of heart 
can be used for studying the influence of drugs together 
with any covariates related to the study population on car-
diac physiology. Their use allow for testing various effects of 
drugs on pathways that may lead to cardiac effects. These 
models consist of the mechanism-based nodes, describ-
ing the physiology of single cardiac cells and they require 
information on the interaction of a drug candidate with each 
component of the pathway.7 Alternative minimal models may 
be used to answer specific questions, which require less 
detailed information and are therefore potentially more prac-
tical in the early drug development stage.8–10 Demonstrating 
applicability and limitations of such models is highly desir-
able for  expansion of the systems pharmacology approach in 
the area of  assessing cardiotoxicity to overcome the limited 
conditions under which the clinical TQT (thorough QT/QTc) 
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We aimed to investigate the application of combined mechanistic pharmacokinetic (PK) and pharmacodynamic (PD) modeling 
and simulation in predicting the domperidone (DOM) triggered pseudo-electrocardiogram modification in the presence 
of a CYP3A inhibitor, ketoconazole (KETO), using in vitro–in vivo extrapolation. In vitro metabolic and inhibitory data were 
incorporated into physiologically based pharmacokinetic (PBPK) models within Simcyp to simulate time course of plasma DOM 
and KETO concentrations when administered alone or in combination with KETO (DOM+KETO). Simulated DOM concentrations 
in plasma were used to predict changes in gender-specific QTcF (Fridericia correction) intervals within the Cardiac Safety 
Simulator platform taking into consideration DOM, KETO, and DOM+KETO triggered inhibition of multiple ionic currents in 
population. Combination of in vitro–in vivo extrapolation, PBPK, and systems pharmacology of electric currents in the heart 
was able to predict the direction and magnitude of PK and PD changes under coadministration of the two drugs although some 
disparities were detected.
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studies are performed (where many permutations of real-life 
scenarios cannot be tested despite the use of some arbitrary 
supratherapeutic concentrations as a conservative safety 
margin). The current study provides such a case for the car-
diotoxicity output expected from a combined administration 
of domperidone (DOM) and KETO where there are potential 
pharmacokinetics (PK) and pharmacodynamics (PD) interac-
tion combinations.
DOM, a peripheral dopamine antagonist, is rapidly and 
almost completely absorbed after oral administration, with a 
reported oral bioavailability in the range of 13–23%.11 This 
low bioavailability may be the result of the poor solubility 
of DOM at an alkaline pH,12,13 and its extensive first pass 
metabolism, as it is extensively metabolized, through multiple 
pathways, by CYP3A, with some contributions from CYP1A2, 
2D6, and 2C19.14 DOM is believed to be a low-risk alternative 
to cisapride, as a gastroprokinetic agent, after the latter was 
withdrawn in many markets due to its cardiotoxic  potential. 
However, early studies of high-dose DOM showed QTc 
prolongation and arrhythmias as side effects.15 Additionally, 
recent reports have shown that DOM prolongs cardiac repo-
larization by blocking the rapid component of the delayed-
rectifier potassium current (IKr) in a concentration-dependent 
manner with an in vitro IC50 value of 162 and 57 nmol/l mea-
sured in hERG-transfected Chinese hamster ovary cells and 
HEK293 cells, respectively.16,17 Due to this potential side 
effect of DOM at increased plasma levels, coadministration 
of DOM and KETO is either not recommended or contraindi-
cated as studies in healthy volunteers have shown a threefold 
increase in the exposure of DOM, in the presence of KETO, 
possibly due to the inhibition of CYP3A4-mediated metab-
olism; therefore, alternative drug combinations are often 
suggested.18
This DOM-KETO coadministration study provided the 
opportunity to establish the usefulness, as well as limitations, 
of in vitro–in vivo extrapolation modeling and simulation in 
predicting the extent of the proarrhythmic potency of CYP 
(cytochrome P450) enzyme substrates in the presence of 
inhibitors. The interactions are mechanistically modeled at 
the level of PK as well as PD.
reSUlTS
Validation of PK simulations
The DOM compound file was validated using nine sets of 
observed clinical data, of which 80% of the trial simulations 
were able to reasonably capture the summary PK parameters 
viz Cmax, area under the curve, and Tmax. Although some in vitro 
parameters were fitted based on a test study, the use of mech-
anistic physiologically based pharmacokinetic (PBPK) models 
allowed the in vivo extrapolation of these parameters and sub-
sequent successful prediction of PK parameters, in compari-
son to the validation study set. The results for the compound 
file validation are presented in the Supplementary  Materials 
online section (Supplementary 1; Supplementary Tables 
S1–S4; Supplementary Figures S1–S4).
The steady-state (day 7) predicted DOM (10 mg, four doses 
daily, at 4 h intervals) concentration–time profile (Mean ± SD) 
superimposed with observed data, with and without coad-
ministration of CYP3A inhibitor KETO (200 mg every 12 h), for 
men and women and KETO alone, is presented in Figures 1 
and 2 respectively. A summary of comparison of observed 
and simulated PK parameters is presented in Table 1.
QTc simulations and ΔQTc analysis
Obtained results are presented separately for women and 
men cohorts for all studied scenarios. QTcF and ΔQTc values 
for DOM alone, KETO alone, and DOM + KETO combination 
are presented in Figures 3 and 4.
Predicted individual ΔQTc values calculated as the indi-
vidual difference between baseline QTcF and QTcF derived 
from the simulated ECG signal after the drugs ingestion are 
presented in Figure 5.
DISCUSSIOn
PK–PD modeling and simulation is widely used to describe 
the factors affecting the QT interval and drug influence on 
the QT interval duration.3 The methods applied can be listed 
among the top-down approaches. In these cases, the neces-
sary elements of the analysis are either clinical or preclinical 
in vivo data, which can be further correlated with the clinical 
end points (i.e., QTc/ΔQTc/QRS/ΔQRS). The models covari-
ates include drug triggered, in vitro measured currents inhibi-
tion, drug concentration, sex, age, etc.3 Once established, 
models can be further used for various scenarios testing, 
dose, and dosing optimization. The main obstacle of such an 
approach is the need of operating at the clinical data level 
(top-down approach) what narrows usability which is limited 
to the tested drug.
There are additional approaches that can help to under-
stand the drug effects on the heart which involve computational 
models to simulate the drugs action and their influence on the 
electrical activity of the heart. The relatively simplest methods 
focus on single cardiomyocyte, however, these suffer from lack 
of direct correlation with much more complex clinical reality. The 
most sophisticated whole-heart modeling approaches offer a 
full insight into the organ level effects.7 The major concern with 
their practical and wide implementation lies paradoxically in the 
complexity of the utilized models and methods which need spe-
cialized knowledge, a wide range of assumptions and signifi-
cant computational resources. In the current work, we propose 
and validate a case study using bottom-up approach, which 
allows for a reliable and mechanistic insight into the electro-
physiological phenomena on the left ventricular wall level 
(one-dimensional simulation). This method is computationally 
efficient enough to run simulations at the population level.
DOM and KETO coapplication was chosen as the basis for 
this case study. Such treatment is not a recommended combi-
nation, due to the potential proarrhythmic side effects of DOM 
at increased plasma levels, which we were able to assess 
using a PBPK model–based approach.15,18 The PBPK model, 
used to simulate the kinetics of DOM, was able to recover its 
plasma concentration profile after an intravenous dose and var-
ious single oral doses (see Supplementary Materials online) 
within twofold of the observed values. The fasted simulations 
of an oral tablet dosing were underpredicted in some cases 
(Supplementary Materials online). This under prediction may 
be an artifact of using the reported mean observed profile data 
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for comparison, or the small number of subjects (n = 5) might 
have low small-intestinal pH and thus have a high in vivo solu-
bility of DOM, which is not representative of the general popula-
tion. Also, the in vitro solubility data for DOM was from a single 
reference and may not necessarily capture the actual observed 
variability in in vivo solubility. The PBPK model was also able 
to recover the steady-state plasma levels after multiple dos-
ing with and without the coadministration of KETO (Figure 1). 
The predicted increase in the exposure of DOM with KETO 
(area under the curve ratio) was 2.8 ± 0.4-fold, which correlated 
well with the observed 3.5-fold increase.15 Data for competi-
tive and time-dependent inhibition of CYP3A4 were included 
in the DOM compound file, but this had minimal impact on the 
amount of active CYP3A4 in the liver or gastrointestinal tract, 
due to the high Ki, Kapp, and Kinact values (Supplementary 
Table S6 online).
Figure 1  Predicted steady-state (day 7) systemic concentration of domperidone (10 simulated trials: grey solid lines; mean profile without 
inhibitor: black solid line; with inhibitor: black dotted line) superimposed with observed data (without inhibitor: triangles; with inhibitor: circles) 
in healthy (a) men and (b) women volunteers.
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The apparent Caco-2 permeability and the phys-chem 
data resulted in a two- to threefold under prediction of Cmax, 
and incorporation of only CYP3A4 metabolism data for DOM 
resulted in an under prediction of clearance.19,20 So, the model 
was fit to the observed clinical data for a 20 mg oral dose, and 
the values for effective jejunal permeability (Peff, man), intrin-
sic hepatic clearance, and renal clearance were estimated, 
using the parameter estimation module within Simcyp.21,22 
For a complete mechanistic PK model, these in vitro values 
need to be revisited and also the role of transporters in the 
absorption of DOM needs to be evaluated.
One of the study assumptions states that the multiple drug 
triggered ionic currents inhibition is a sum of their inhibiting 
potency alone (additive effect). Such an assumption does not 
necessarily have its reflection in the human clinical settings 
as the interaction is supposed to be more complex as pre-
sented in the in vitro studies.23 Moreover, there are reports 
suggesting different current reactions regarding the drugs 
dosing order.24 The results suggest a partial additive effect, 
not a clear synergism although what has to be emphasized is 
that both of the cited studies were done in the in vitro/ex vivo 
animal settings and the situation can be considerably differ-
ent in the complex in vivo situation.
The most commonly used surrogate of the drug proar-
rhythmic potency is the in vitro measured IKr current inhibition. 
Such an approach is fully reasonable as the majority of drugs 
that were shown to have torsadogenic potency in man are IKr 
(hERG) blockers. As a result, most efforts in examining the 
safety of new compounds have concentrated on assessing 
their effects on the hERG channel. There are, however, other 
channels of which drug triggered blockades are known to be 
connected with the risk of the Torsades de Pointes. The most 
important is KCNQ, responsible for the IKs potassium current 
occurrence. Some of the known torsadogenic drugs, includ-
ing terfenadine, are potent IKs current inhibitors in vitro.
25,26 
This is consistent with the statement that torsadogenic com-
pounds are hERG blockers although not all hERG blockers 
are necessarily dangerous.8 It is likely that the change in 
ECG is an interplay between various channels inhibition. In 
general, it is postulated that the IKs current is one of the most 
overlooked sources of cardiovascular liability in drug safety 
assessment.5 Other ionic currents that are postulated to play 
significant role in the drug safety profile include peak sodium 
(INa) and late calcium (ICaL) currents.
27
In the current study, information about the IKs and ICaL 
currents inhibition were added to the in vitro measured IKr 
current modification data. As it was not possible to assess 
the IKs and ICaL IC50 prediction accuracy, the imperfection 
of the prediction can be caused by the imperfect assess-
ment of the drug triggered alteration of the slow delayed 
rectifier potassium current and late calcium current. One 
of the main methodological assumptions of the current 
study accounted for is the simple summation of the in vivo 
PD effect of concomitantly given drugs and the analysis of 
the DOM and KETO interaction cannot be effectively com-
pleted without considering the same. Clinical effect under 
prediction observed in the results, which is more prominent 
in men in comparison to women is probably a consequence 
of the improperly coupled effects of the two tested drugs. 
In the most likely scenario, the DOM influence on the IKs 
Figure 2  Predicted systemic concentrations of ketoconazole over time (10 simulated trials: solid lines; mean profile: black line; 5th and 95th 
percentile profile: grey dotted lines) and superimposed with observed data (open circles) in healthy volunteers, for an oral dose of 200 mg.
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Table 1 Observed (Obs) vs. Simcyp-simulated (Sim) PK parameters for single DOM (40 mg), KETO (200 mg) dosage, and DOM+KETO combination
Dose Cmax (ng/ml) SD
area under the 
curve (ng* h/ml) SD Tmax (h) SD/range
Obs DOM 23.5 7.4 249.0 65.3 9.0 0.5–14
Sim DOM 23.3 2.6 260.2 38.0 12.7 0.04
Obs DOM+KETO 67.9 21.1 878.1 267.7 5.0 0.5–14.1
Sim DOM+KETO 56.7 4.4 737.8 71.0 12.8 0.03
Obs KETO 5,690.0 1,760.0 70,400.0 2,810.0 2.1 0.5–24.0
Sim KETO 5,371.4 435.4 56,160.8 5,016.3 5.5 6.22
DOM, domperidone; KETO, ketoconazole.
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current was underpredicted, and the total in vivo effect of 
the two given drugs does not simply sum up. The largest 
under predictions are seen after the first and the last dose. 
This could be due to the under prediction of the combined 
ionic current disruption at the lowest concentration, if we 
assume that the nonlinear concentration–inhibition rela-
tionship is not fully capturing the steepness (or shallow-
ness) of the true relationship. Cardiac Safety Simulator was 
also able to differentiate between genders in the drug-trig-
gered QTcF modification although ΔQTcF values were over 
predicted for females what suggests that the baseline value 
prediction was imperfect (Table 2 and Figure 5). However, 
it should be noted that the simulated vs. observed ΔQTcF 
values were calculated in different ways due to the inability 
of simulations to create the placebo effects and relying only 
on baseline correction (see Methods).
The observations suggest that additional differentiation 
between sexes at the cardiac cell level are needed to improve 
the predictability.28 On the other hand, the simulation results 
stay in agreement with other literature sources which point 
out female gender as a risk factor for the drug-triggered 
heart electrophysiology modification.29 Taking it altogether, 
one may suggest that the observed higher male suscepti-
bility was specific for this particular study population only. 
Figure 3  Observed (black squares) and predicted (empty squares) QTcF and DQTcF values (±SD) in domperidone single and in ketoconazole 
single scenarios.
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This may highlight the well-known concept of repeatability of 
single clinical studies as discussed below.
The requirement for repeated clinical studies and possi-
bility of using confirmatory studies (in Learn–Confirm cycle) 
have been the subject of much debate.30 Ability to avoid 
repeat clinical study depends on whether there is consistency 
between mechanistically derived expectations (what we have 
learnt independently) and the observations made. The incon-
sistency between predictions and observations does not nec-
essarily question the modeling outcome, but it may highlight 
specific conditions in the clinical study which made it deviate 
from expectations. In the current case, in contrast to the obser-
vations by Boyce et al.15, the simulated ΔQTc values clearly 
suggest that significant cardiac risk connected not only with 
Figure 4  Observed (black squares) and predicted (empty squares) QTc and DQTcF values for domperidone plus ketoconazole therapy (±SD) 
in domperidone with ketoconazole scenario.
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the studied drug combination but also with the single DOM. 
While the first conclusion one may draw would be related to 
the shortcomings of the model, evidence from other literature 
supports the outcome of the modeling as recent reports sug-
gest that DOM carries significant cardiac risk and should be 
withdrawn from the market.31,32 The simulation results, from 
the risk assessment point of view, suggest potential risks.33,34 
It is in this line that the European Medicines Agency initiated 
reviewing the DOM via the Belgian Medicines Agency.35
The main aim of the clinical trial run was to establish the 
DOM and KETO combination safety margin. The simulation 
confirmed many of the clinical trial findings—the PK interac-
tion between DOM and KETO resulted in the QT prolonga-
tion and such combination is not recommended (Table 2).
COnClUSIOnS
Combination of mechanistic PBPK-Tox modeling and sim-
ulation tools (Simcyp and Cardiac Safety Simulator) was 
able to recover the PK and toxicological effect of DOM 
administered as a single drug and its combination with 
the pharmacokinetically and pharmacodynamically inter-
acting drug (KETO), through simulations largely based on 
collated in vitro data. Generating such in vitro data on the 
properties of a drug and its impact on the cardiac action 
potential currents, at the drug discovery stage, could be 
beneficial. By simulating the interaction in virtual popula-
tions, extreme cases can also be evaluated by identifying 
the characteristics of the most susceptible individuals. QTc 
predictions for more than one drug rely substantially on the 
total effect calculations. It is therefore crucial to work on 
the models describing such effects. This study, despite of 
the disparities between the observed and predicted values, 
highlights the potential of using model-based drug develop-
ment and simulation as a cardiac safety assessment tool, 
which has to be thoroughly validated before being routinely 
utilized for the drug development process. The strength and 
weakness of the proposed approach lies in the combination 
of various modeling and simulation techniques including 
quantitative structure -activity relationship (QSAR), PBPK, 
PD, and systems biology. Uncertainty in the unknown and 
estimated parameters has possibly contributed to the mis-
match between clinical observations and the predicted 
values yet the general conclusions on the drugs triggered 
ECG modifications can be made. Such systematic devia-
tion has not been observed in other simulations and studies 
including recently published work where the cardiac effect 
expressed as the QTc value of six central nervous system 
drugs was predicted using the Cardiac Safety Simulator.36 
Hence this mismatches could be attributed to lack of full 
knowledge of drug-specific data and/or special conditions 
in the clinical study, which made them different to other 
more representative cases. A potential solution to this chal-
lenge can be implementation of the middle-out approaches 
where available preclinical and clinical data can be used to 
improve predictability of the models.
Figure 5  Concentration–ΔQTcF relation. Relation between plasma domperidone (a,b) and ketoconazole (c,d) concentration and difference in 
QTcF from baseline (ΔQTcF), in men (a,c) and women (b,d) on single and combination therapy at steady state (day 7 of dosing). Domperidone 
alone (empty squares); domperidone in combination (black squares); ketoconazole alone (empty circles); ketoconazole in combination (black 
circles).
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MeTHODS
PK simulations
Simcyp (v11.1) platform was used for the PK simulations. A 
Simcyp library compound file for DOM was developed using 
physiochemical information from the PubChem compound 
database and the DrugBank.19,37 Drug parameters such as 
the blood to plasma ratio (B/P), fraction unbound in plasma 
(fu), and the volume of distribution (VSS) were predicted using 
inbuilt models in Simcyp v11.1.38–41 A solubility–pH profile 
was obtained from Zhang et al.12 to predict the in vivo solu-
bility. The physiochemical absorption and distribution param-
eters are summarized in Supplementary Table S5 online.
Using Baculovirus-insect cell–expressed recombinant 
CYPs, Ward et al.14 established that DOM is metabo-
lized through three different pathways mainly catalyzed by 
CYP3A4. Chang et al.42 reported that DOM exhibits mecha-
nism-based inhibition of CYP3A4 and also acts as a competi-
tive inhibitor resulting in a clinically significant increase in the 
exposure of CYP3A4 substrates. The metabolism and inhibi-
tion model parameters are summarized in Supplementary 
Table S6 online.
Initial compound file validation against clinical data showed 
that in the absence of detailed information on the supersatura-
tion state following stomach emptying to intestine and the gut 
wall permeability, the model underpredicted the drug absorp-
tion and the elimination profile (data not shown). So, subse-
quently, the observed clinical data21 were fitted by obtaining 
optimal values for the intestinal permeability, intrinsic clear-
ance, and renal clearance using the parameter estimation 
module within Simcyp. The final values used during the com-
pound file validation and simulation studies were 4.596 × 10−4 
cm/s, 37.6 µl/min/106 hepatocytes, and 2.55 l/h, respectively.
The KETO compound file was taken from the Simcyp 
compound database, with the modification of CLpo of 8.3 
l/h to account for the dose-dependent elimination kinetics 
of KETO.43 The DOM compound file was validated against 
published clinical data from various sources for both intrave-
nous and oral dosing conditions under fasted and fed states, 
based on the outputs for a simulated virtual population.11,21,44
To assess the proarrhythmic potency of DOM (alone and 
in the presence of KETO), the plasma concentration values, 
at the same time points as reported by Boyce et al.15 were 
Table 2 Cardiac Safety Simulator–simulated ΔQTcF values for single DOM (40 mg) and DOM+KETO combination (mean ± 95% CI)
Time of the 
study (h)
Domperidone Ketoconazole Combination
Predicted male  
ΔQTcF (ms) 95% CI
Predicted male 
ΔQTcF (ms) 95% CI
Predicted male 
ΔQTcF (ms) 95% CI
144 0.83 0.69 0.97 2.97 1.85 4.09 4.69 2.57 6.81
144.5 0.29 −8.49 9.08 2.41 −7.64 12.46 7.44 −1.42 16.29
145 8.04 −1.84 17.91 16.55 8.45 24.66 16.71 7.85 25.57
146 15.01 5.28 24.74 17.48 6.90 28.06 23.03 13.38 32.69
148 15.90 5.37 26.43 21.92 12.82 31.01 22.34 11.78 32.90
149 25.06 19.20 30.93 25.17 14.65 35.70 34.17 28.44 39.91
152 15.45 8.96 21.94 23.34 13.91 32.76 21.70 14.53 28.87
153 21.82 13.01 30.62 20.59 8.03 33.15 30.07 21.03 39.11
156 5.70 −2.01 13.41 12.50 −0.23 25.23 11.52 3.33 19.71
156.5 11.31 0.69 21.93 3.85 −5.95 13.65 20.55 9.96 31.13
157 9.01 −2.16 20.17 15.62 5.17 26.07 19.21 8.47 29.95
158 −1.39 −13.35 10.57 8.80 −2.64 20.23 7.80 −3.90 19.51
160 −3.92 −16.27 8.42 −2.66 −13.67 8.34 3.37 −9.01 15.74
168 −0.66 −14.64 13.33 2.80 1.76 3.84 3.50 −11.36 18.36
Time of the 
study (h)
Predicted  
female ΔQTcF (ms) 95% CI
Predicted female 
ΔQTcF (ms) 95% CI
Predicted  
female ΔQTcF (ms) 95% CI
144 1.02 0.75 1.30 3.00 2.30 3.69 2.52 2.21 2.83
144.5 14.35 2.68 26.02 15.21 2.09 28.33 25.30 13.11 37.50
145 15.95 8.56 23.34 14.55 5.27 23.82 28.43 21.30 35.55
146 11.79 1.23 22.34 21.07 11.34 30.80 23.20 12.33 34.06
148 28.69 15.24 42.13 29.26 17.35 41.17 36.18 22.40 49.96
149 35.69 19.87 51.51 23.87 11.28 36.45 42.00 25.93 58.08
152 32.74 19.97 45.50 31.26 17.93 44.60 36.08 23.23 48.93
153 31.79 20.73 42.84 37.69 21.43 53.94 34.66 23.59 45.73
156 25.36 13.43 37.30 19.26 −0.86 39.38 27.25 15.30 39.20
156.5 25.95 16.38 35.52 24.01 10.55 37.46 37.72 28.09 47.35
157 25.91 18.11 33.71 16.45 −4.05 36.96 39.41 31.04 47.78
158 18.97 13.50 24.43 25.42 9.90 40.94 30.94 25.15 36.72
160 9.49 −0.77 19.74 5.87 −3.94 15.69 16.76 6.38 27.14
168 −0.54 −5.21 4.13 3.05 2.35 3.75 0.90 −3.82 5.63
CI, confidence interval; DOM, domperidone; KETO, ketoconazole.
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recorded from the Simcyp outputs and used as input param-
eters for the Cardiac Safety Simulator platform (v1.0) to sim-
ulate the drug-induced QTcF (Fridericia correction) interval 
change.45,46
The in vitro IKr ionic current inhibition data for both drugs 
were taken from the literature, and the IKs and ICaL currents 
inhibition were predicted with the Cardiac Safety Simulator 
built-in QSAR models.17,47,48 The QSAR models were used 
as it was hypothesized that DOM and KETO can also inhibit 
currents other than IKr. As the QSAR models utilize in vitro 
setting as the independent parameters, it was assumed 
that the parameters mimic the literature-derived informa-
tion for the hERG channels inhibition for DOM and KETO 
respectively. Chemical structures encoded as the sdf files 
were downloaded from PubChem resources. The full set of 
Cardiac Safety Simulator input parameters are presented in 
 Supplementary Table S7 online.
Population-dependent parameters (age, sex, and heart 
rate) were set up to mimic the clinical trial settings (24 individ-
uals consisting of 14 men and 10 women; age 18–39; weight 
range: 53.8–98.8 kg). In the original study, 1 of the 24 healthy 
individuals was Afro-Caribbean; in our study, we assumed 
that all 24 were North European Caucasian individuals. To 
account for potential statistical sampling issues and popula-
tion variability, each clinical study was simulated 10 times, 
where the size of study in each trial was the same as the clini-
cal study, and it was assumed that all individuals completed 
the study.
The DOM and KETO interaction was based on the clinical 
study design by Boyce et al.15, wherein the effects of DOM 
and KETO, alone and in combination, on the heart rate cor-
rected QT interval in healthy volunteers were assessed. The 
population PK behavior was predicted in healthy volunteers, 
however since Boyce et al. studied the gender differences in 
the effects of DOM, this effect was also analyzed for female 
only and male only virtual populations.39,45,46
eCg simulations
The Cardiac Safety Simulator system was used to simulate 
the drugs triggered ECG modification. The platform com-
bines a physiologically based electrophysiological model 
of the human left ventricular cardiomyocytes (TNNP - ten 
Tusscher-Noble-Noble-Panfilov) and a database of human 
physiological, genotypic, and demographical data enabling 
prediction of the QT prolongation in humans based on 
the in vitro data.10 To account for the heterogeneities in 
ionic currents between endocardial, midmyocardial, and 
epicardial cells, a 1D fiber model paced at the endocar-
dial side was used. The default 50:30:20 distribution of 
the endo-, mid-, and epicardial cells was used together 
with the diffusion coefficient equals to 0.0016 cm2/ms. 
The forward Euler method was used to integrate model equa-
tions. For a one-dimensional string of cells, the results are 
used to calculate a pseudo-ECG. A space step and a time 
step are, by default, set to Δx = 0.01 mm and Δt = 0.01 ms.
Drug-triggered ionic current modifications were incorpo-
rated in specific equations describing IKr, IKs, and ICaL currents 
by multiplying them by the inhibition factor, which was either 
provided or QSAR predicted and described the concentra-
tion-dependent ionic current inhibition. The inhibition factors 
were calculated using the Hill equation (Eq. 1).
Inhibitionfactor =
1
1+(IC /Concentration( mol/l))50 µ n
 (1)
Simulation time was set to 10,000 ms, and during the 
ECG analysis, the first and last beats were withdrawn from 
the analysis to assure stability and avoid computation bias. 
The population variability effect was mimicked by applying 
the virtual population generator as described previously.46,49 
The heart rate and plasma ions variability were represented 
in the simulation by adding circadian variation.49–51 The Car-
diac Safety Simulator system was able to accurately recover 
the RR (inter-beat) intervals (data not shown).
The total ionic currents inhibition by interacting drugs was 
assumed to be the sum of their inhibiting potencies alone. 
During the ECG simulation study, the average predicted con-
centrations, from Simcyp outputs, at certain time points for 
single DOM and DOM with KETO were used. The predicted 
mean DOM concentrations on day 7 following administration 
of the drug alone, or in combination with KETO, were used 
as part of the input to the Cardiac Safety Simulator system. 
Based on these values, ionic current inhibition was calcu-
lated using the Hill equation (both parameters namely IC50 
and “n” were taken from the available literature as reported 
in Supplementary Table S7 online). For the IKs predicted IC50 
value, the “n” parameter was assumed to be 1. To enable 
direct comparison, the selected time points were similar to 
those at which the observed QTcF values were derived. All 
predicted QTcF values were presented as mean and SD. For 
the ΔQTc, 95% CI was used as the dispersion measure to 
keep the data presentation method used in the original study.
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Study Highlights
WHaT IS THe CUrrenT KnOWleDge On THe 
TOPIC?
 3 Due to the potential side effect, coadministration 
of DOM and KETO is either not  recommended 
or contraindicated as studies have shown a 
threefold increase in the exposure of DOM, in 
the presence of KETO, possibly due to the inhi-
bition of CYP3A4-mediated metabolism.
WHaT QUeSTIOn DID THIS STUDY aDDreSS?
 3 Is it possible to simulate PK and PD effects 
of the concomitantly given KETO and DOM 
with the use of the mechanistic model at the 
 population level?
WHaT THIS STUDY aDDS TO OUr KnOWleDge
 3 The combination of mechanistic PBPK, Tox 
modeling, and simulation tools were able to 
 recover the PK and toxicological effect of 
DOM administered as a single drug and its 
combination with the pharmacokinetically and 
 pharmacodynamically interacting drug (KETO), 
through simulations largely based on previously 
collated in vitro data.
HOW THIS MIgHT CHange ClInICal 
PHarMaCOlOgY anD THeraPeUTICS
 3 This study highlights the potential of using mod-
el-based drug development and simulation as a 
valuable cardiac safety assessment tool.
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